Tyra Biosciences (NASDAQ:TYRA) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Tyra Biosciences (NASDAQ:TYRA) issued its earnings results on Wednesday. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09, Zacks reports.

Tyra Biosciences Price Performance

TYRA traded up $0.84 during trading on Thursday, hitting $20.34. The stock had a trading volume of 348,897 shares, compared to its average volume of 146,375. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -12.11 and a beta of 1.02. The company has a 50 day moving average price of $18.87 and a 200-day moving average price of $17.77. Tyra Biosciences has a one year low of $10.38 and a one year high of $23.12.

Insiders Place Their Bets

In related news, COO Daniel Bensen sold 3,502 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $20.00, for a total value of $70,040.00. Following the transaction, the chief operating officer now directly owns 427,981 shares in the company, valued at $8,559,620. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 15.40% of the company’s stock.

Wall Street Analysts Forecast Growth

TYRA has been the topic of several research analyst reports. Wedbush restated an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research note on Thursday. Oppenheimer dropped their price target on Tyra Biosciences from $28.00 to $25.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $23.00 price target on shares of Tyra Biosciences in a report on Wednesday, July 3rd.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.